AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 32 min read$STOK

Ticho Barry sold $55K of STOK

Ticho Barry (CHIEF MEDICAL OFFICER) sold 1,795 shares of Stoke Therapeutics, Inc. (STOK) at $30.58 on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Ticho Barry
Published Jun 3, 2026, 9:33 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 3, 2026, 9:34 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$STOK
Neutral
medium confidence
Mentioned
$STOK
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$STOKNeutralLow
01

Why it matters

The disclosure may slightly influence retail/short-term sentiment but does not introduce new fundamental information about Stoke’s pipeline or finances.

02

Market read

This is a routine insider-sale filing; expected impact is limited unless paired with other negative catalysts not present here.

03

What to watch

The sale size ($54.9k) is relatively small versus typical institutional flows; the 10b5-1 structure reduces interpretability of intent.

Relevance 6/10Novelty 2/10Timing: Filed June 3; sale executed June 1.

Background

SEC Form 4 reports insider transactions; this one is an open-market sale by the Chief Medical Officer under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$STOKNeutralMedium confidence
Context

Stoke Therapeutics CMO Ticho Barry sold 1,795 shares in an open-market transaction disclosed via SEC Form 4 on June 1 under a 10b5-1 plan.

Expected impact

Likely limited/short-lived impact; any reaction is more sentiment-driven than fundamental.

Evidence & confidence

The filing provides a disclosed sale price and size, but no new company-specific operational or clinical catalyst is included.

Market effects

Sector

Minimal; this is company-specific insider activity with no stated sector/regulatory/clinical update.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Even with 10b5-1, repeated insider selling can be interpreted as risk management rather than conviction, potentially weighing on sentiment if investors are already skeptical.

Key entities

  • issuer
    Stoke Therapeutics, Inc.

    Subject of the insider transaction disclosure (SEC Form 4).

  • insider
    Ticho Barry

    Chief Medical Officer who sold 1,795 shares at $30.58 on June 1, 2026 under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

STOK insider trading history →

Related articles

SEP 4
$STOKMedAI 8/10

Stoke and Biogen report long-term zorevunersen Dravet data

Stoke Therapeutics and Biogen reported long-term data for zorevunersen, an investigational Dravet syndrome therapy, showing sustained seizure reductions and cognitive improvements over four years. The Phase 3 EMPEROR trial has completed enrollment, with data expected in Q3 2027 ahead of a planned U.S. NDA submission.

grafa.com1 min
SEP 4
$BIIBMedAI 8/10

Biogen Inc.: Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrom

Stoke Therapeutics and Biogen presented long-term data at the 16th European Epilepsy Congress, showing zorevunersen's potential in treating Dravet syndrome. The Phase 1/2a and OLE studies demonstrated durable seizure reductions, cognitive and behavioral improvements, and quality of life enhancements. The Phase 3 EMPEROR study data is expected in Q3 2027, aiming to complete the U.S. NDA submission. Zorevunersen was generally well tolerated, with some patients treated for over 5 years. Dravet synd

finanznachrichten.de2 min
SEP 1
$STOKMedAI 8/10

Stoke Therapeutics and Biogen to present four-year zorevunersen data at epilepsy congress

Stoke Therapeutics (STOK) and Biogen (BIIB) will present four-year data on zorevunersen, their experimental Dravet syndrome treatment, at the European Epilepsy Congress. The data shows sustained cognitive and behavioral improvements, reduced seizures, and a generally safe profile. 77% of patients remain in extension studies. Zorevunersen is in Phase 3 trials, with results expected in Q3 2027. The therapy has received FDA and EMA designations but is not yet approved.

yahoo.com2 min
SEP 1
$STOKMedAI 8/10

Stoke Therapeutics, Inc.: Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 1

Stoke Therapeutics (STOK) and Biogen (BIIB) presented 4-year data from Phase 1/2a studies of zorevunersen, an investigational treatment for Dravet syndrome, at the 16th European Epilepsy Congress. The data showed sustained improvements in cognition, behavior, and seizure reduction, with a generally well-tolerated safety profile. The Phase 3 EMPEROR study is ongoing, with results expected in Q3 2027.

finanznachrichten.de3 min
AUG 18
$STOKMed

Stoke Therapeutics’ Dravet Trial Tops Enrollment Target With Zero Dropouts

Stoke Therapeutics (NASDAQ:STOK) said its Phase III EMPEROR trial for zorevunersen in Dravet syndrome met enrollment targets with zero dropouts. The FDA granted breakthrough therapy designation. The study will assess seizures and Vineland-3 cognitive and behavioral endpoints. Stoke plans a rolling NDA start in Q1 2027, completing in Q3 2027.

yahoo.com4 min
AUG 11
$STOKMedAI 8/10

Stoke Therapeutics (STOK) Q2 2026 Earnings Call Transcript

Stoke Therapeutics (STOK) reported Phase III EMPEROR enrollment completion of 162 patients and said a Phase III readout is expected in Q3 2027. Rolling NDA submissions are planned for Q1 2027, with a potential early 2028 launch of zorevunersen. Q2 revenue was $9.3M and net loss $61.6M. Pro forma cash was about $420M.

fool.com7 min